Article 54 adds a second opinion, not a veto

Which devices actually trigger the procedure

Article 54(1) limits the consultation to a specific slice of the class system: Class III implantable devices, and Class IIb active devices intended to administer and/or remove a medicinal product from the body. A notified body carrying out conformity assessment under Article 52 for a device in that slice has to forward the clinical evaluation assessment report to an expert panel before it can issue a certificate, not as an optional courtesy but as a step Article 54 builds into the assessment itself. Devices outside that slice — most Class IIb devices, and every Class IIa and Class I device — never reach this step; the class-and-function test at the front of the article does the sorting, and nothing about a device's novelty alone pulls it into scope if it fails that test.

What Article 54(2) excuses

Even inside that slice, three situations skip the consultation. A certificate renewal doesn't trigger it again. Neither does a device the same manufacturer has modified from one already on the market for the same intended purpose, provided the manufacturer shows the modification doesn't adversely affect the benefit-risk ratio. And neither does a device whose clinical evaluation principles a Common Specification already addresses, provided the notified body confirms the device actually complies with it — the same document this blog has covered as binding in a way a voluntary standard doesn't. A manufacturer hoping to skip the panel by citing a Common Specification has to show compliance with it, not just point to its existence.

What the panel actually produces

Once a submission is in scope, the documentation goes to a screening step first; MDCG 2019-3 describes that screening deciding, within a matter of weeks, whether a full panel opinion is actually warranted, so not every eligible submission automatically draws the complete consultation. Where a panel opinion does go forward, independent clinical, scientific, and technical experts, organized by field, review the notified body's clinical evaluation assessment report and issue a scientific opinion on the claimed benefit-risk ratio, the clinical evaluation plan's fit with the intended purpose, and the adequacy of the planned post-market clinical follow-up. That opinion goes to the notified body and the manufacturer; it doesn't travel any further in the certification chain on its own.

The notified body isn't bound, but it has to say why

This is where “consultation” earns its name instead of functioning as a hidden veto. The notified body has to take the panel's opinion into account, but Article 54 doesn't require it to follow that opinion. A notified body reaching a different conclusion can still issue the certificate, on the condition that it documents a justification for departing from the panel's view — a justification that becomes part of the record a competent authority can later review. That's a different structure than an unannounced Annex IX audit, which checks a quality system directly rather than routing a judgment call through a second reviewer whose opinion the first can accept or reject on the record.

Where this meets the file

A clinical evaluation tracker for a Class III implantable program needs a field the ordinary MDR timeline doesn't: whether the device falls inside Article 54(1) at all, which Article 54(2) exemption might apply and the evidence behind it, and — where the consultation runs its course — the date the expert panel's opinion arrived, kept separate from the date the notified body certifies. Collapsing those into a single “notified body review” milestone erases the distinction Article 54 is built around: an opinion from one body, a decision that stays with another. An Article 54 scoping worksheet built around the regulation's own three-part test is previewed in the launch catalog. If your program tracks this pathway differently, the shelf takes that correction directly.